

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup>:
A61K 39/00, 39/39, 48/00, C07K 14/47

A1

(11) International Publication Number:

WO 99/20302

(43) International Publication Date:

29 April 1999 (29.04.99)

(21) International Application Number:

PCT/US98/22145

(22) International Filing Date:

20 October 1998 (20.10.98)

(30) Priority Data:

08/954,643

20 October 1997 (20.10.97)

US

(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application

US Filed on 08/954,643 (CIP) 20 October 1997 (20.10.97)

(71) Applicant (for all designated States except US): AVANT IMMUNOTHERAPEUTICS, INC. [US/US]; 119 Fourth Avenue, Needham, MA 02194 (US).

(72) Inventors: and

- (75) Inventors/Applicants (for US only): RITTERSHAUS, Charles, W. [US/US]; 65 Garden Street, Malden, MA 02148 (US). THOMAS, Lawrence, J. [US/US]; 1 Fox Ridge Road, Easton, MA 02375 (US).
- (74) Agent: YANKWICH, Leon, R.; Yankwich & Associates, 130 Bishop Allen Drive, Cambridge, MA 02139 (US).


(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

## Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: XENOGENEIC CHOLESTERYL ESTER TRANSFER PROTEIN (CETP) FOR MODULATION OF CETP ACTIVITY



(57) Abstract

Methods for modulating cholesteryl ester transfer protein (CETP) activity and the plasma levels of lipoproteins involved in heart disease involve administration of a non-endogenous CETP or a plasmid-based vaccine for expression of such non-endogenous CETP to elicit production in a mammal of antibodies that recognize (bind to) the mammal's native (endogenous) CETP.